Posted by Michael Wonder on 12 Jul 2021
‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’
12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion worldwide last year.
However, MSD Korea is struggling with limited reimbursement for Keytruda in Korea.
